Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-08-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: dialysisheartbonecancerfailure
  Phrases that lowered it: patient10healthystemhiv
• Sponsor's past termination rate: 27.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 12 (raises risk) · Drug's FDA history
• Sponsor's past trials: 904 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 209 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 337105 (lowers risk) · Drug's FDA history
• Minimum age: not given (raises risk) · Who can join
• Drug's FAERS reports with a death: 19.9% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 86.7% (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 55830 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors NCT02100891 · started 2013 · scored riskier than 87% of active trials terminated
• Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation NCT02259348 · started 2014 · scored riskier than 94% of active trials terminated
• A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity NCT03032783 · started 2017 · scored riskier than 99% of active trials completed
• A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives NCT01532635 · started 2012 · scored riskier than 99% of active trials terminated
• Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer NCT00963872 · started 2010 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.